Bio-Path Stock Price, News & Analysis (NASDAQ:BPTH)

$1.62 -0.04 (-2.41 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$1.62
Today's Range$1.55 - $1.74
52-Week Range$1.53 - $10.10
Volume59,838 shs
Average Volume113,268 shs
Market Capitalization$181.42 million
P/E Ratio-2.19
Dividend YieldN/A
Beta3.01

About Bio-Path (NASDAQ:BPTH)

Bio-Path logoBio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.

Receive BPTH News and Ratings via Email

Sign-up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:BPTH
CUSIPN/A
Phone+1-832-7421357

Debt

Debt-to-Equity RatioN/A
Current Ratio7.61%
Quick Ratio7.61%

Price-To-Earnings

Trailing P/E Ratio-2.18783783783784
Forward P/E Ratio-2.02
P/E GrowthN/A

Sales & Book Value

Annual Sales$10,000.00
Price / Sales1,835.95
Cash FlowN/A
Price / CashN/A
Book Value$0.86 per share
Price / Book1.88

Profitability

Trailing EPS($0.74)
Net Income$-6,750,000.00
Net MarginsN/A
Return on Equity-72.98%
Return on Assets-59.29%

Miscellaneous

Employees12
Outstanding Shares11,340,000

Bio-Path (NASDAQ:BPTH) Frequently Asked Questions

What is Bio-Path's stock symbol?

Bio-Path trades on the NASDAQ under the ticker symbol "BPTH."

When did Bio-Path's stock split? How did Bio-Path's stock split work?

Bio-Path shares reverse split on Thursday, February 8th 2018. The 1-10 reverse split was announced on Friday, February 9th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 9th 2018. An investor that had 100 shares of Bio-Path stock prior to the reverse split would have 10 shares after the split.

How were Bio-Path's earnings last quarter?

Bio-Path Holdings Inc (NASDAQ:BPTH) posted its quarterly earnings data on Thursday, November, 9th. The company reported ($0.20) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.20). View Bio-Path's Earnings History.

When will Bio-Path make its next earnings announcement?

Bio-Path is scheduled to release their next quarterly earnings announcement on Tuesday, March, 13th 2018. View Earnings Estimates for Bio-Path.

Where is Bio-Path's stock going? Where will Bio-Path's stock price be in 2018?

2 brokers have issued 12-month price objectives for Bio-Path's stock. Their predictions range from $15.00 to $20.00. On average, they expect Bio-Path's share price to reach $17.50 in the next twelve months. View Analyst Ratings for Bio-Path.

Are investors shorting Bio-Path?

Bio-Path saw a decrease in short interest in January. As of January 31st, there was short interest totalling 830,396 shares, a decrease of 53.7% from the January 12th total of 1,794,678 shares. Based on an average trading volume of 874,021 shares, the days-to-cover ratio is presently 1.0 days. Currently, 0.8% of the company's stock are sold short.

Who are some of Bio-Path's key competitors?

Who are Bio-Path's key executives?

Bio-Path's management team includes the folowing people:

  • Peter Henry Nielsen, Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer, Treasurer (Age 67)
  • Ulrich W. Mueller Ph.D., Secretary (Age 50)
  • Douglas P. Morris, Director (Age 78)
  • Paul D. Aubert, Independent Director
  • Heath W. Cleaver CPA, Independent Director (Age 43)
  • Mark P Colonnese, Independent Director (Age 61)

Who owns Bio-Path stock?

Bio-Path's stock is owned by many different of institutional and retail investors. Top institutional investors include Sabby Management LLC (16.17%), Anson Funds Management LP (11.84%), Hudson Bay Capital Management LP (0.68%), Renaissance Technologies LLC (6.03%) and Millennium Management LLC (4.92%). View Institutional Ownership Trends for Bio-Path.

Who sold Bio-Path stock? Who is selling Bio-Path stock?

Bio-Path's stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Bio-Path.

Who bought Bio-Path stock? Who is buying Bio-Path stock?

Bio-Path's stock was bought by a variety of institutional investors in the last quarter, including Sabby Management LLC, Anson Funds Management LP, Hudson Bay Capital Management LP and Renaissance Technologies LLC. View Insider Buying and Selling for Bio-Path.

How do I buy Bio-Path stock?

Shares of Bio-Path can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bio-Path's stock price today?

One share of Bio-Path stock can currently be purchased for approximately $1.62.

How big of a company is Bio-Path?

Bio-Path has a market capitalization of $181.42 million and generates $10,000.00 in revenue each year. The company earns $-6,750,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. Bio-Path employs 12 workers across the globe.

How can I contact Bio-Path?

Bio-Path's mailing address is 4710 Bellaire Blvd Ste 210, BELLAIRE, TX 77401-4505, United States. The company can be reached via phone at +1-832-7421357 or via email at [email protected]


MarketBeat Community Rating for Bio-Path (BPTH)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  153 (Vote Outperform)
Underperform Votes:  98 (Vote Underperform)
Total Votes:  251
MarketBeat's community ratings are surveys of what our community members think about Bio-Path and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Bio-Path (NASDAQ:BPTH) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $17.50$17.50$17.50$35.00
Price Target Upside: 464.52% upside464.52% upside464.52% upside1,066.67% upside

Bio-Path (NASDAQ:BPTH) Consensus Price Target History

Price Target History for Bio-Path (NASDAQ:BPTH)

Bio-Path (NASDAQ:BPTH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/13/2017HC WainwrightReiterated RatingBuy -> Buy$45.00 -> $15.00N/AView Rating Details
4/5/2017Maxim GroupSet Price TargetBuy$20.00HighView Rating Details
8/11/2016Rodman & RenshawSet Price TargetBuy$50.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Bio-Path (NASDAQ:BPTH) Earnings History and Estimates Chart

Earnings by Quarter for Bio-Path (NASDAQ:BPTH)

Bio-Path (NASDAQ BPTH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2018($0.02)N/AView Earnings Details
11/9/2017Q3 2017($0.20)($0.20)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.20)($0.30)ViewListenView Earnings Details
5/11/2017Q1 2017($0.20)($0.10)ViewN/AView Earnings Details
3/15/201712/31/2016($0.30)($0.10)$0.01 millionViewListenView Earnings Details
11/9/2016Q316($0.20)($0.20)$2.50 millionViewListenView Earnings Details
8/9/2016Q2($0.20)($0.20)ViewN/AView Earnings Details
5/11/2016Q1($0.10)($0.20)$2.33 millionViewListenView Earnings Details
3/16/2016Q4($0.10)($0.20)$1.46 millionViewN/AView Earnings Details
11/10/2015Q315($0.20)ViewN/AView Earnings Details
8/11/2015Q2 2015($0.30)($0.10)ViewN/AView Earnings Details
5/12/2015Q1 2015($0.20)ViewN/AView Earnings Details
3/17/2015Q4 2014$0.10($0.20)ViewN/AView Earnings Details
11/17/2014Q3 2014($0.10)($0.10)ViewN/AView Earnings Details
8/18/2014Q214($0.10)($0.10)ViewN/AView Earnings Details
5/16/2014Q1 2014($0.10)($0.10)ViewN/AView Earnings Details
4/2/2014$0.10$0.10ViewN/AView Earnings Details
11/15/2013Q3 2013($0.10)($0.20)ViewN/AView Earnings Details
8/15/2013Q2 2013($0.10)($0.10)ViewN/AView Earnings Details
5/16/2013Q1 2013($0.10)($0.10)ViewN/AView Earnings Details
11/16/2012Q3 2012($0.10)($0.10)ViewN/AView Earnings Details
8/16/2012Q2 2012($0.10)($0.10)ViewN/AView Earnings Details
5/17/2012Q1 2012($0.10)($0.10)ViewN/AView Earnings Details
4/3/2012Q4 2011($0.10)ViewN/AView Earnings Details
11/15/2011Q3 2011($0.20)($0.10)ViewN/AView Earnings Details
8/15/2011Q2 2011($0.10)($0.10)ViewN/AView Earnings Details
5/17/2011Q1 2011($0.20)($0.10)ViewN/AView Earnings Details
3/31/2011Q4 2010($0.10)($0.10)ViewN/AView Earnings Details
11/15/2010Q3 2010($0.10)ViewN/AView Earnings Details
8/17/2010Q2 2010($0.10)ViewN/AView Earnings Details
4/3/2009Q4 2008($0.50)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Bio-Path (NASDAQ:BPTH) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.8 EPS
Next Year EPS Consensus Estimate: $-0.9 EPS

Dividends

Dividend History for Bio-Path (NASDAQ:BPTH)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Bio-Path (NASDAQ BPTH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.20%
Insider Trades by Quarter for Bio-Path (NASDAQ:BPTH)
Institutional Ownership by Quarter for Bio-Path (NASDAQ:BPTH)

Bio-Path (NASDAQ BPTH) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/13/2015Michael J GarrisonDirectorBuy7,343$1.22$8,958.46View SEC Filing  
7/9/2015Michael J GarrisonDirectorBuy8,724$1.17$10,207.08View SEC Filing  
7/8/2015Michael J GarrisonDirectorBuy60,000$1.19$71,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Bio-Path (NASDAQ BPTH) News Headlines

Source:
DateHeadline
 Brokerages Anticipate Bio-Path Holdings Inc (BPTH) to Announce -$0.20 Earnings Per Share Brokerages Anticipate Bio-Path Holdings Inc (BPTH) to Announce -$0.20 Earnings Per Share
www.americanbankingnews.com - February 14 at 1:08 AM
Bio-Path Holdings Inc (BPTH) Sees Large Decrease in Short InterestBio-Path Holdings Inc (BPTH) Sees Large Decrease in Short Interest
www.americanbankingnews.com - February 11 at 1:52 AM
Bio-Path Holdings (BPTH) Announces 1-for-10 Reverse Stock SplitBio-Path Holdings (BPTH) Announces 1-for-10 Reverse Stock Split
www.streetinsider.com - February 10 at 6:07 AM
Bio-Path Holdings Announces 1-for-10 Reverse Stock Split - GlobeNewswire (press release)Bio-Path Holdings Announces 1-for-10 Reverse Stock Split - GlobeNewswire (press release)
globenewswire.com - February 9 at 3:27 PM
Bio-Path Holdings to Present at the BIO CEO & Investor ConferenceBio-Path Holdings to Present at the BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 5:52 AM
Bio-Path Holdings Appoints Paul Aubert to its Board of Directors - GlobeNewswire (press release)Bio-Path Holdings Appoints Paul Aubert to its Board of Directors - GlobeNewswire (press release)
globenewswire.com - February 5 at 3:20 PM
Bio-Path Holdings Appoints Paul Aubert to its Board of DirectorsBio-Path Holdings Appoints Paul Aubert to its Board of Directors
finance.yahoo.com - February 5 at 3:20 PM
Pre-Market Technical Scan on Drug Delivery Equities -- Bio-Path, Alkermes, PetMed Express, and Valeant Pharma - PR Newswire (press release)Pre-Market Technical Scan on Drug Delivery Equities -- Bio-Path, Alkermes, PetMed Express, and Valeant Pharma - PR Newswire (press release)
www.prnewswire.com - February 1 at 3:20 PM
Analyzing Merrimack Pharmaceuticals (MACK) & Bio-Path (BPTH)Analyzing Merrimack Pharmaceuticals (MACK) & Bio-Path (BPTH)
www.americanbankingnews.com - January 25 at 3:14 PM
Form 8-K BIO-PATH HOLDINGS INC For: Dec 29 - StreetInsider.comForm 8-K BIO-PATH HOLDINGS INC For: Dec 29 - StreetInsider.com
www.streetinsider.com - January 3 at 12:03 AM
HC Wainwright Reaffirms "Buy" Rating for Bio-Path (BPTH)HC Wainwright Reaffirms "Buy" Rating for Bio-Path (BPTH)
www.americanbankingnews.com - December 31 at 3:38 PM
Bio-Path Holdings Provides Clinical Update and 2018 Business OutlookBio-Path Holdings Provides Clinical Update and 2018 Business Outlook
finance.yahoo.com - December 29 at 5:27 PM
-$0.02 Earnings Per Share Expected for Bio-Path Holdings, Inc. (BPTH) This Quarter-$0.02 Earnings Per Share Expected for Bio-Path Holdings, Inc. (BPTH) This Quarter
www.americanbankingnews.com - December 25 at 1:16 PM
Financial Comparison: Bio-Path (BPTH) & Brainstorm Cell Therapeutics (BCLI)Financial Comparison: Bio-Path (BPTH) & Brainstorm Cell Therapeutics (BCLI)
www.americanbankingnews.com - November 27 at 5:22 PM
 Analysts Anticipate Bio-Path Holdings, Inc. (BPTH) Will Post Earnings of -$0.02 Per Share Analysts Anticipate Bio-Path Holdings, Inc. (BPTH) Will Post Earnings of -$0.02 Per Share
www.americanbankingnews.com - November 20 at 1:28 AM
Bio-Path Holdings, Inc. (BPTH) Given New $1.50 Price Target at Bio-Path Holdings, Inc. (BPTH) Given New $1.50 Price Target at
www.americanbankingnews.com - November 19 at 4:20 PM
Bio-Path Holdings, Inc. (BPTH) Releases Quarterly  Earnings Results, Hits EstimatesBio-Path Holdings, Inc. (BPTH) Releases Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - November 10 at 12:51 PM
Bio-Path Holdings Inc (BPTH): How Does It Impact Your Portfolio?Bio-Path Holdings Inc (BPTH): How Does It Impact Your Portfolio?
finance.yahoo.com - November 10 at 12:41 PM
Bio-Path Holdings Reports Third Quarter 2017 Financial ResultsBio-Path Holdings Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 5:52 PM
Bio-Path reports 3Q lossBio-Path reports 3Q loss
finance.yahoo.com - November 9 at 5:52 PM
Bio-Path Holdings Highlights Advancements in Preclinical Discovery Efforts - GlobeNewswire (press release)Bio-Path Holdings Highlights Advancements in Preclinical Discovery Efforts - GlobeNewswire (press release)
globenewswire.com - November 9 at 12:29 AM
Bio-Path Holdings Highlights Advancements in Preclinical Discovery EffortsBio-Path Holdings Highlights Advancements in Preclinical Discovery Efforts
finance.yahoo.com - November 6 at 5:51 PM
Bio-Path Holdings (BPTH) Announces $4M Registered Direct Offering of Common Stock and WarrantsBio-Path Holdings (BPTH) Announces $4M Registered Direct Offering of Common Stock and Warrants
www.streetinsider.com - November 3 at 5:20 PM
Bio-Path Holdings, Inc. Announces $4 Million Registered Direct OfferingBio-Path Holdings, Inc. Announces $4 Million Registered Direct Offering
finance.yahoo.com - November 3 at 5:20 PM
Bio-Path Holdings to Announce Third Quarter 2017 Financial Results on November 10, 2017Bio-Path Holdings to Announce Third Quarter 2017 Financial Results on November 10, 2017
finance.yahoo.com - November 3 at 8:25 AM
Bio-Path Holdings, Inc. (BPTH) Scheduled to Post Quarterly Earnings on WednesdayBio-Path Holdings, Inc. (BPTH) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 1 at 4:06 AM
Bio-Path Holdings (BPTH) and Palatin Technologies (PTN) Financial ComparisonBio-Path Holdings (BPTH) and Palatin Technologies (PTN) Financial Comparison
www.americanbankingnews.com - October 30 at 9:28 AM
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH)Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH)
finance.yahoo.com - October 23 at 4:37 PM
Is It Time To Buy Bio-Path Holdings Inc (BPTH)?Is It Time To Buy Bio-Path Holdings Inc (BPTH)?
finance.yahoo.com - October 11 at 6:11 PM
Bio-Path Holdings, Inc. (BPTH) Expected to Post Earnings of -$0.02 Per ShareBio-Path Holdings, Inc. (BPTH) Expected to Post Earnings of -$0.02 Per Share
www.americanbankingnews.com - October 11 at 12:20 PM
Bio-Path (BPTH) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowBio-Path (BPTH) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 5:52 PM
Bio-Path Holdings to Present at the Rodman & Renshaw Annual Healthcare Conference - GlobeNewswire (press release)Bio-Path Holdings to Present at the Rodman & Renshaw Annual Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - September 5 at 11:19 PM
Bio-Path Holdings to Present at the Rodman & Renshaw Annual Healthcare ConferenceBio-Path Holdings to Present at the Rodman & Renshaw Annual Healthcare Conference
finance.yahoo.com - September 5 at 6:17 PM
-$0.02 EPS Expected for Bio-Path Holdings, Inc. (BPTH) This Quarter-$0.02 EPS Expected for Bio-Path Holdings, Inc. (BPTH) This Quarter
www.americanbankingnews.com - September 4 at 4:28 AM
Bio-Path Holdings, Inc. (NASDAQ:BPTH) PT Set at $5.00 by HC WainwrightBio-Path Holdings, Inc. (NASDAQ:BPTH) PT Set at $5.00 by HC Wainwright
www.americanbankingnews.com - August 13 at 3:32 PM
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Releases  Earnings ResultsBio-Path Holdings, Inc. (NASDAQ:BPTH) Releases Earnings Results
www.americanbankingnews.com - August 11 at 2:34 PM
Bio-Path Holdings (BPTH) CEO Peter Nielsen on Q2 2017 Results - Earnings Call TranscriptBio-Path Holdings' (BPTH) CEO Peter Nielsen on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 10 at 5:50 PM
Bio-Path reports 2Q lossBio-Path reports 2Q loss
finance.yahoo.com - August 10 at 5:50 PM
Bio-Path Holdings to Announce Second Quarter 2017 Financial Results on August 10, 2017 - GlobeNewswire (press release)Bio-Path Holdings to Announce Second Quarter 2017 Financial Results on August 10, 2017 - GlobeNewswire (press release)
globenewswire.com - August 4 at 4:58 PM
Bio-Path Holdings to Announce Second Quarter 2017 Financial Results on August 10, 2017Bio-Path Holdings to Announce Second Quarter 2017 Financial Results on August 10, 2017
finance.yahoo.com - August 3 at 6:08 PM
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Scheduled to Post Quarterly Earnings on TuesdayBio-Path Holdings, Inc. (NASDAQ:BPTH) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:17 AM
Bio-Path Holdings Receives Notice of Allowance for Key U.S. Composition of Matter PatentBio-Path Holdings Receives Notice of Allowance for Key U.S. Composition of Matter Patent
finance.yahoo.com - July 31 at 4:44 PM
Bio-Path Holdings Receives Notice of Allowance for Key US Composition of Matter Patent - GlobeNewswire (press release)Bio-Path Holdings Receives Notice of Allowance for Key US Composition of Matter Patent - GlobeNewswire (press release)
globenewswire.com - July 20 at 11:21 PM
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Stock Rating Reaffirmed by HC WainwrightBio-Path Holdings, Inc. (NASDAQ:BPTH) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - July 20 at 8:42 AM
Bio-Path Holdings (BPTH) Granted Allowance for Key US Composition of Matter Patent for DNAbilize by USPTO - StreetInsider.comBio-Path Holdings (BPTH) Granted Allowance for Key US Composition of Matter Patent for DNAbilize by USPTO - StreetInsider.com
www.streetinsider.com - July 19 at 5:52 PM
Bio-Path Holdings Appoints Mark Colonnese to its Board of Directors - NasdaqBio-Path Holdings Appoints Mark Colonnese to its Board of Directors - Nasdaq
www.nasdaq.com - July 17 at 5:04 PM
Bio-Path Holdings Appoints Mark Colonnese to its Board of DirectorsBio-Path Holdings Appoints Mark Colonnese to its Board of Directors
finance.yahoo.com - July 17 at 12:23 PM
Stonegate Capital Partners Initiates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) - Baystreet.caStonegate Capital Partners Initiates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) - Baystreet.ca
www.baystreet.ca - June 30 at 4:49 PM
Bio-Path Holdings (BPTH) CEO Peter Nielsen on Q1 2017 Results - Earnings Call TranscriptBio-Path Holdings' (BPTH) CEO Peter Nielsen on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 4:36 PM
Bio-Path Holdings (BPTH) Presents At Oppenheimer 27th Annual Healthcare Conference - SlideshowBio-Path Holdings (BPTH) Presents At Oppenheimer 27th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 23 at 1:49 AM

SEC Filings

Bio-Path (NASDAQ:BPTH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Bio-Path (NASDAQ:BPTH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Bio-Path (NASDAQ BPTH) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.